

ImmunoScape raises \$11M to accelerate vital immunotherapies

17 August 2020 | News

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines



Singapore based biotech startup ImmunoScape has announced that it has raised USD\$11 million (SGD \$14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (Utec) in Japan, and NPR Holdings in Indonesia.

ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 related programs on three continents.

"There is an urgent need to understand how the T-cell immune response contributes to COVID-19 immunity and can be leveraged for vaccine design," said ImmunoScape co-founder and Chief Operating Officer Dr. Alessandra Nardin. "In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals. We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners."

ImmunoScape also has established collaborations with several vaccine development companies, including the San Diego-based Arcturus which is running clinical trials in Singapore.

ImmunoScape's technology was based on work begun at Stanford University, and continued at A*STAR of Singapore, where the company was established in 2017. ImmunoScape has received support from A*STAR and its commercialization arm A*ccelerate, as well as Enterprise Singapore. Technical founder Dr. Evan Newell, PhD, previously an A*STAR Science Fellow, is now based at Seattle's Fred Hutchinson Cancer Research Center.